PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17306762-2 2007 ATP (1 mM) and the P2X7R agonist BzATP (100 microM) significantly increased p38 MAPK phosphorylation in WT mice, and these effects were absent in the hippocampal slices of P2X7R(-/-) mice. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 33-38 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 19-24 17437542-6 2007 LPC facilitated the sustained increase in the intracellular Ca(2+) concentration ([Ca(2+)](i)) through P2X7R channels activated by ATP or BzATP. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 138-143 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 103-108 17306762-2 2007 ATP (1 mM) and the P2X7R agonist BzATP (100 microM) significantly increased p38 MAPK phosphorylation in WT mice, and these effects were absent in the hippocampal slices of P2X7R(-/-) mice. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 33-38 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 172-177 12759456-5 2003 This blebbing was comparably induced by the P2X7R-selective agonist BzATP and was blocked by P2X7R inhibitors KN-62 and oxidized ATP. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 68-73 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 44-49 16817206-2 2006 Using cocultures of rat cortical neurons and microglia, we show that ATP and the more potent P2X(7) agonist benzoylbenzoyl-ATP (BzATP) cause neuronal cell injury. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 108-126 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 93-99 16817206-2 2006 Using cocultures of rat cortical neurons and microglia, we show that ATP and the more potent P2X(7) agonist benzoylbenzoyl-ATP (BzATP) cause neuronal cell injury. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 128-133 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 93-99 16817206-3 2006 The deleterious effects of BzATP-treated microglia were prevented by nonselective P2X antagonists (PPADS and oxidized ATP) and by the more selective P2X(7) antagonist Brilliant Blue G. Similar concentrations of BzATP caused release of superoxide and nitric oxide from isolated microglia, and neuronal cell injury was attenuated by a superoxide dismutase mimetic and by a peroxynitrite decomposition catalyst, suggesting a role for reactive oxide species. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 27-32 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 149-155 16269410-7 2005 Studies using MC3T3-E1 osteoblasts and MLO-Y4 osteocytes confirmed that PGE2 release was suppressed by P2X7R blockade, whereas the P2X7R agonist BzATP enhanced PGE2 release. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 145-150 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 131-136 16541451-6 2006 Isolated porcine theca cells maintained in primary cultures and tested with 1 mM ATP or 250 microM Bz-ATP, a specific agonist of P2X7, responded with an increase in intracellular calcium concentration, as demonstrated in cells loaded with fluo-4 as calcium indicator. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 99-105 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 129-133 16122875-2 2005 Activation of P2X7 receptors by ATP or its agonist BzATP induces Ca2+ influx from extracellular space, followed by the formation of non-selective membrane pores that is permeable to larger molecules, such as fluorescent dye. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 51-56 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 14-18 16122875-6 2005 In contrast, both U73122 and U73343 inhibited the sustained [Ca2+]i increase either prior or after the activation of P2X7 receptor channels by ATP and BzATP. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 151-156 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 117-130 16122875-7 2005 In addition, these U-compounds inhibited the influx of ethidium bromide induced by ATP and BzATP, suggesting possible PLC-independent blockage of the process of P2X7-associated channel and pore formations by U-compounds in C57BL/6 mouse microglial cells. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 91-96 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 161-165 15005852-11 2004 Benzoyl-benzoyl-ATP (BzATP, a P2X7 agonist, 300 microM) induced nuclear translocation of NF-kappaB after 3 h in approximately 45% of rabbit osteoclasts. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 0-19 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 30-34 15005852-11 2004 Benzoyl-benzoyl-ATP (BzATP, a P2X7 agonist, 300 microM) induced nuclear translocation of NF-kappaB after 3 h in approximately 45% of rabbit osteoclasts. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 21-26 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 30-34 15005852-14 2004 Treatment with BzATP for 30 minutes increased nuclear localization of NF-kappaB in osteoclasts from WT but not KO mice, showing involvement of P2X7 receptors. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 15-20 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 143-147 12551918-2 2003 ATP and BzATP stimulate O(2)(-)* production through purinergic receptors, primarily the P2X(7) receptor. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 8-13 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 88-103 11943809-2 2002 Activation of P2X(7) purinoceptors by ATP or 3"-O-(4-benzoyl)-benzoyl ATP (BzATP) induces the formation of cytolytic pores and provokes release of interleukin-1beta from immune cells. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 75-80 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 14-20 12598620-5 2003 ATP produced an inward current in patch-clamped astrocytes with properties characteristic of P2X7 receptor activation: the current was amplified in low divalent cation medium, blocked by pyridoxal phosphate-6-azophenyl-2",4"-disulfonic acid (PPADS), and more potently activated by 3"-O-(4-benzoyl)benzoyl ATP (BzATP) than by ATP itself. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 310-315 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 93-106 12935357-9 2003 We found that the P2X7-directed ligand BzATP was unable to prevent LPS-induced death, whereas 2-MeS-ATP and 2-Cl-ATP, which bind to multiple P2X and P2Y receptors were able to protect mice from LPS-induced death. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 39-44 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 18-22 11943809-2 2002 Activation of P2X(7) purinoceptors by ATP or 3"-O-(4-benzoyl)-benzoyl ATP (BzATP) induces the formation of cytolytic pores and provokes release of interleukin-1beta from immune cells. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 45-73 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 14-20 11943809-5 2002 However, when ADP and AMP, but not UTP or adenosine, were applied after a brief exposure to ATP or BzATP, they activated P2X(7) receptors in a dose-dependent manner. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 99-104 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 121-127 34239315-14 2021 SA or ASA also inhibited the inward current evoked by P2X7R agonist, BZATP. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 69-74 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 54-59 34863113-11 2021 Furthermore, activation of P2X7 receptor by BzATP restored the TAT-Fyn (39-57)-reduced cortical susceptibility to CSD. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 44-49 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 27-40 34544431-9 2021 RESULTS: Sholl analysis of Iba1-stained cells showed retraction of microglial ramifications 1 day after injection of P2X7 receptor agonist BzATP into mouse retinae. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 139-144 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 117-130 11414659-4 2001 BzATP was more potent than ATP at the three species homologues and exhibited highest potency for rat P2X7 receptors suggesting that channel closure time was related to agonist potency. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 0-5 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 101-105 11414659-5 2001 Furthermore, BzATP potency for the P2X7 receptor could be modified by changing extracellular ionic concentrations or by mutating the receptor and modifications which increased agonist potency also increased the time taken for channel closure. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 13-18 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 35-39 1331096-2 1992 We have confirmed the presence of these two ATP receptor types in the BAC1.2F5 murine macrophage cell line and have identified 3"-O-(4-benzoyl)benzoyl-ATP (BzATP) as a selective and potent agonist for the so-called P2z or pore-forming ATP receptor type. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 127-154 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 235-247 1331096-2 1992 We have confirmed the presence of these two ATP receptor types in the BAC1.2F5 murine macrophage cell line and have identified 3"-O-(4-benzoyl)benzoyl-ATP (BzATP) as a selective and potent agonist for the so-called P2z or pore-forming ATP receptor type. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 156-161 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 235-247 35254644-4 2022 Treatment of primary cultured microglia with BzATP, a P2X7R agonist, mimicked the effects of cell proliferation and migration in COH retinas through the intracellular MEK/ERK signaling pathway. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 45-50 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 54-59 35588154-6 2022 Extending these studies, we found that transient in vitro stimulation of P2RX7 using the ATP analog BzATP led to enhanced B16 melanoma control by CD8+ T cells. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 100-105 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 73-78 33081303-4 2020 ATP or BzATP (a prototypic P2X7R agonist) significantly enhanced the inductions of PAD4 and CitH3 in a P2X7R-dependent manner and intracellular Ca2+ influx, PKCalpha activation, and NADPH oxidase-dependent reactive oxygen species (ROS) production play critical roles in this ATP-P2X7R-mediated NETosis. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 7-12 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 27-32 35293345-13 2022 ELISA confirmed that the IL-1beta and IL-18 levels repressed in the BZATP (P2X7R agonist) group, while the trend was opposite in the A438079 (P2X7R inhibitor) group. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 68-73 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 75-80 33081303-4 2020 ATP or BzATP (a prototypic P2X7R agonist) significantly enhanced the inductions of PAD4 and CitH3 in a P2X7R-dependent manner and intracellular Ca2+ influx, PKCalpha activation, and NADPH oxidase-dependent reactive oxygen species (ROS) production play critical roles in this ATP-P2X7R-mediated NETosis. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 7-12 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 103-108 33081303-4 2020 ATP or BzATP (a prototypic P2X7R agonist) significantly enhanced the inductions of PAD4 and CitH3 in a P2X7R-dependent manner and intracellular Ca2+ influx, PKCalpha activation, and NADPH oxidase-dependent reactive oxygen species (ROS) production play critical roles in this ATP-P2X7R-mediated NETosis. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 7-12 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 103-108 33081303-5 2020 In our MCAO animal model, NETosis was markedly suppressed by treatment with apyrase, an enzyme hydrolyzing ATP, but enhanced by co-treatment of BzATP, confirming ATP-P2X7R-mediated NETosis. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 144-149 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 166-171 30098388-1 2019 Whole-cell patch clamp recordings demonstrated that in the dentate gyrus (DG) as well as in the CA3 area of mouse hippocampal slices the prototypic P2X7 receptor (R) agonist dibenzoyl-ATP (Bz-ATP) induced inward current responses both in neurons and astrocytes. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 189-195 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 148-161 33071753-1 2020 The P2X7 receptor (P2X7) is a cell surface ligand-gated ion channel, activated by its physiological nucleotide agonist ATP and a synthetic analog (BzATP). 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 147-152 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 4-17 31445901-10 2019 The number of microglia cells was increased after addition of BzATP, the agonist of P2X7R, to the culture medium of primary rat microglia cells. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 62-67 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 84-89 32566102-6 2020 Similarly, P2X7R inhibition by Brilliant Blue G (BBG) reduced mRNA and protein levels of profibrosis markers, while the P2X7R agonist BzATP accelerated the TGF-beta1-induced CFs activation. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 134-139 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 120-125 29501771-9 2018 Finally, we observed that P2 x 7R agonist BzATP reversed the inhibition effect of GRGM-13 on RGC-5 cell apoptosis, ROS level and p-p38 expression, while si-P2 x 7R inhibited oxidative stress-induced phosphorylation of p38. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 42-47 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 26-33 30536959-7 2019 Likewise, stimulation of P2X7 receptor on hematopoietic cells by BzATP enhanced the release of osteoclastogenesis-stimulating signaling molecules to a similar extent as supraphysiological loading. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 65-70 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 25-38 30458799-7 2018 RESULTS: In primary microglia, BV-2 microglial cells and BMDM, P2X7 agonist BzATP triggered AMPK activation and LC3II accumulation through reactive oxygen species (ROS) and CaMKKII pathways, and these effects were abolished by P2X7 antagonist A438079 and P2X7 deficiency. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 76-81 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 63-67 30458799-7 2018 RESULTS: In primary microglia, BV-2 microglial cells and BMDM, P2X7 agonist BzATP triggered AMPK activation and LC3II accumulation through reactive oxygen species (ROS) and CaMKKII pathways, and these effects were abolished by P2X7 antagonist A438079 and P2X7 deficiency. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 76-81 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 227-231 30458799-7 2018 RESULTS: In primary microglia, BV-2 microglial cells and BMDM, P2X7 agonist BzATP triggered AMPK activation and LC3II accumulation through reactive oxygen species (ROS) and CaMKKII pathways, and these effects were abolished by P2X7 antagonist A438079 and P2X7 deficiency. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 76-81 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 227-231 31100367-12 2019 In contrast, downregulating P2X7R by mimic-187 or A-438079 treatment comparably increased PWT and PWL values in IR-injured mice, while upregulating P2X7R by inhibitor-187 or BzATP treatment decreased PWT and PWL values in sham-operated mice. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 174-179 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 28-33 30796903-8 2019 BzATP, a P2X7R activator, evoked [Ca2+]i increase in Hek293 cells with heterologous expression of P2X7R (Hek293-P2X7R cells) and the same dose of ATP-induced [Ca2+]i was more obvious in Hek293-P2X7R cells than in Hek293 cells. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 0-5 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 9-14 30796903-8 2019 BzATP, a P2X7R activator, evoked [Ca2+]i increase in Hek293 cells with heterologous expression of P2X7R (Hek293-P2X7R cells) and the same dose of ATP-induced [Ca2+]i was more obvious in Hek293-P2X7R cells than in Hek293 cells. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 0-5 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 98-103 30796903-8 2019 BzATP, a P2X7R activator, evoked [Ca2+]i increase in Hek293 cells with heterologous expression of P2X7R (Hek293-P2X7R cells) and the same dose of ATP-induced [Ca2+]i was more obvious in Hek293-P2X7R cells than in Hek293 cells. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 0-5 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 98-103 30796903-8 2019 BzATP, a P2X7R activator, evoked [Ca2+]i increase in Hek293 cells with heterologous expression of P2X7R (Hek293-P2X7R cells) and the same dose of ATP-induced [Ca2+]i was more obvious in Hek293-P2X7R cells than in Hek293 cells. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 0-5 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 98-103 30796903-9 2019 Application of BzATP activated an inward current of Hek293-P2X7R in a dose dependent manner. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 15-20 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 59-64 29021225-7 2018 P2X7 activation by BzATP also induced PAD4 expression and activity in mouse kidney in vivo. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 19-24 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 0-4 29397411-5 2018 Further, the expression of both proteins increased after 24 h CdCl2/TGF-beta1 treatment of precision-cut lung slices, but decreased after 72 h. Using immunohistochemistry, the activation of the P2X7R with the agonist BzATP modulated the aquaporin 5 immunoreactivity in the alveolar epithelium of precision-cut lung slices from wild-type but not from P2X7R knockout mice. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 217-222 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 194-199 28669743-8 2017 On the other hand, BzATP-mediated increased number of activated microglia and increased survival kinase levels in addition to increased caspase-1 and IL-1beta levels indicate the complex nature of the P2X7 receptor-mediated signaling in neuronal injury. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 19-24 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 201-214 26481422-4 2015 Our results showed that activation of P2 x 7R by BzATP resulted in increase in the gene expression of osteoblastic markers, the activity of alkaline phosphatase and bone mineralization, and decrease in the gene expression of adipogenic markers and the number of adipocytes generated by BMSCs. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 49-54 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 38-45 28848393-9 2017 The P2X7 receptor was implicated in the mechanosensitive priming of IL-1beta mRNA in vivo, as the antagonist Brilliant Blue G (BBG) blocked the increased expression, the agonist BzATP mimicked the pressure-dependent rise in IL-1beta, and the rise was absent in P2X7 knockout mice. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 178-183 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 4-17 28848393-9 2017 The P2X7 receptor was implicated in the mechanosensitive priming of IL-1beta mRNA in vivo, as the antagonist Brilliant Blue G (BBG) blocked the increased expression, the agonist BzATP mimicked the pressure-dependent rise in IL-1beta, and the rise was absent in P2X7 knockout mice. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 178-183 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 4-8 28716092-14 2017 CONCLUSIONS: These results reveal that P2X7 mediates BzATP-induced microglial cell death and specific release of IL1 family cytokines, indicating the important role of P2X7 in neuroinflammation and implying the potential of targeting P2X7 for the treatment of neuroinflammatory disorders. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 53-58 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 168-172 28716092-14 2017 CONCLUSIONS: These results reveal that P2X7 mediates BzATP-induced microglial cell death and specific release of IL1 family cytokines, indicating the important role of P2X7 in neuroinflammation and implying the potential of targeting P2X7 for the treatment of neuroinflammatory disorders. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 53-58 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 168-172 28237817-4 2017 The effect of the prototypic P2X7 receptor agonist Bz-ATP on superficial astrocytes and neurons depended on the drug concentration applied and increased in parallel with the lengthening of the culture period. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 51-57 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 29-42 28163685-6 2017 P2X7 selective agonist (BzATP) induced inward currents dose-dependently. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 24-29 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 0-4 28716092-10 2017 Second, P2X7 agonist BzATP caused cell death of mouse microglia, while this effect was suppressed either by P2X7 knockout or by A-804598 under both basal and pro-inflammatory conditions, which suggests the mediating role of P2X7 in BzATP-induced microglial cell death. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 21-26 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 8-12 28716092-11 2017 Third, BzATP-induced release of IL1 family cytokines including IL1alpha, IL1beta, and IL18 was blocked in P2X7-/- microglia or by A-804598 in pro-inflammatory microglia, while the release of other cytokines/chemokines was independent of P2X7 activation. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 7-12 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 106-110 28716092-11 2017 Third, BzATP-induced release of IL1 family cytokines including IL1alpha, IL1beta, and IL18 was blocked in P2X7-/- microglia or by A-804598 in pro-inflammatory microglia, while the release of other cytokines/chemokines was independent of P2X7 activation. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 7-12 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 237-241 28716092-14 2017 CONCLUSIONS: These results reveal that P2X7 mediates BzATP-induced microglial cell death and specific release of IL1 family cytokines, indicating the important role of P2X7 in neuroinflammation and implying the potential of targeting P2X7 for the treatment of neuroinflammatory disorders. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 53-58 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 39-43 27833023-2 2016 Our findings show that phagocytosis of bio-particles coated with S. aureus or E. coli was blocked by ATP and the P2X7 receptor agonist BzATP, while yeast phagocytosis was not. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 135-140 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 113-117 27393519-3 2016 The pharmacologically isolated NMDA receptor-mediated RGC ON-fEPSP was reduced in the presence of BzATP, an effect which was significantly attenuated by A438079 and other selective P2X7R antagonists A804598 or AF27139. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 98-103 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 181-186 27586846-6 2016 Pharmacological and molecular evidences suggest a major role for P2X7R and P2Y11R in ATP-mediated inhibition of TEC migration: selective activation of these purinergic receptors by BzATP mimics the anti-migratory effect of ATP, which is in turn impaired by their pharmacological or molecular silencing. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 181-186 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 65-70 26481422-10 2015 These data suggest that BzATP activates the differentiation of BMSCs into osteoblasts but not adipocytes by stimulating ERK1/2 and JNK signaling pathways in a P2 x 7R-dependent way. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 24-29 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 159-166 24798220-4 2014 In undifferentiated cells, the P2X7R agonist Bz-ATP accelerated cell cycle entry, which was blocked by the specific P2X7R inhibitor KN-62. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 45-51 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 31-36 25486274-4 2014 Down-regulation of P2X7 by siRNA significantly attenuated ATP- or BzATP-driven migration and invasion of prostate cancer cells in vitro, and inhibited tumor invasiveness and metastases in nude mice. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 66-71 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 19-23 25486274-5 2014 In addition, silencing of P2X7 remarkably attenuated ATP- or BzATP- driven expression changes of EMT/invasion-related genes Snail, E-cadherin, Claudin-1, IL-8 and MMP-3, and weakened the phosphorylation of PI3K/AKT and ERK1/2 in vitro. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 61-66 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 26-30 24948057-7 2014 RESULTS: Selective P2X7R agonist BzATP treatment causes neuronal cell death by causing cytosolic Ca(2+) overload, depletion of Ca(2+) stores, endoplasmic reticulum (ER) stress, and caspase-3 activation (cleaved caspase 3). 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 33-38 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 19-24 24948057-8 2014 Remarkably, taurine (10mM) pretreatment could prevent P2X7R-mediated neuronal cell death by blocking BzATP-mediated ER stress as determined by phosphorylated eukaryotic translation initiation factor 2alpha (peIF2alpha) and C/EBP-homologous protein (CHOP). 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 101-106 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 54-59 25782073-8 2015 P2X7 antagonist BBG reversed the inhibition induced by ATP and BzATP. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 63-68 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 0-4 24798220-4 2014 In undifferentiated cells, the P2X7R agonist Bz-ATP accelerated cell cycle entry, which was blocked by the specific P2X7R inhibitor KN-62. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 45-51 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 116-121 24101734-6 2013 BzATP also elicited inwardly directed nondesensitizing whole-cell ionic currents that were reduced by extracellular Mg(2+) and P2X7 antagonists (BBG and calmidazolium). 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 0-5 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 127-131 24470356-3 2014 Stimulation of P2X7 receptor by ATP (1 mM) or BzATP (500 microM) evoked the mRNA expression and release of proinflammatory cytokines IL-6, TNF-alpha, and the chemokine CCL2 in WT cells but not in P2X7(-/-) cells. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 46-51 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 15-28 24470356-3 2014 Stimulation of P2X7 receptor by ATP (1 mM) or BzATP (500 microM) evoked the mRNA expression and release of proinflammatory cytokines IL-6, TNF-alpha, and the chemokine CCL2 in WT cells but not in P2X7(-/-) cells. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 46-51 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 15-19 20739479-5 2011 The inactivity of alpha,beta-methylene ATP, as well as the potency increases of BzATP and ATP in a low divalent cation (X2(+))-containing superfusion medium suggested the involvement of P2X7 receptors. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 80-85 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 186-190 23727220-3 2013 Whole-cell patch-clamp recordings showed a marked potentiation of the inward current responses both to ATP and the prototypic P2X7 receptor agonist dibenzoyl-ATP (Bz-ATP) at low Ca(2+) and zero Mg(2+) concentrations in the bath medium. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 163-169 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 126-139 23727220-5 2013 The general P2X/P2Y receptor antagonist PPADS and the P2X7 selective antagonists Brilliant Blue G and A-438079 strongly depressed the effect of Bz-ATP. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 144-150 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 54-58 23727220-10 2013 Correspondingly, Bz-ATP led to an increase in active caspase 3 immunoreactivity, indicating a P2X7-controlled apoptosis. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 17-23 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 94-98 22875784-3 2012 In vitro studies using submandibular gland (SMG) cell aggregates isolated from wild-type C57BL/6 mice indicate that treatment with ATP or the high affinity P2X7R agonist 3"-O-(4-benzoyl)benzoyl-ATP (BzATP) induces membrane blebbing and enhances caspase activity, responses that were absent in SMG cell aggregates isolated from mice lacking the P2X7R (P2X7R(-/-)). 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 170-197 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 156-161 22875784-3 2012 In vitro studies using submandibular gland (SMG) cell aggregates isolated from wild-type C57BL/6 mice indicate that treatment with ATP or the high affinity P2X7R agonist 3"-O-(4-benzoyl)benzoyl-ATP (BzATP) induces membrane blebbing and enhances caspase activity, responses that were absent in SMG cell aggregates isolated from mice lacking the P2X7R (P2X7R(-/-)). 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 170-197 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 344-349 22875784-3 2012 In vitro studies using submandibular gland (SMG) cell aggregates isolated from wild-type C57BL/6 mice indicate that treatment with ATP or the high affinity P2X7R agonist 3"-O-(4-benzoyl)benzoyl-ATP (BzATP) induces membrane blebbing and enhances caspase activity, responses that were absent in SMG cell aggregates isolated from mice lacking the P2X7R (P2X7R(-/-)). 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 170-197 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 344-349 22875784-4 2012 Additional studies with SMG cell aggregates indicate that activation of the P2X7R with ATP or BzATP stimulates the cleavage and release of alpha-fodrin, a cytoskeletal protein thought to act as an autoantigen in the development of SS. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 94-99 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 76-81 22134903-3 2012 In this study, a P2X7R agonist (BzATP) was used to activate P2X7R in differentiated NG108-15 neuronal cells. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 32-37 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 17-22 22134903-3 2012 In this study, a P2X7R agonist (BzATP) was used to activate P2X7R in differentiated NG108-15 neuronal cells. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 32-37 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 60-65 22192844-4 2012 BLM treatment or stimulation of the P2X7R with the P2X7R agonist BzATP induced translocation of PKC-beta1 from the cytoplasm to the membrane. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 65-70 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 36-41 22192844-4 2012 BLM treatment or stimulation of the P2X7R with the P2X7R agonist BzATP induced translocation of PKC-beta1 from the cytoplasm to the membrane. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 65-70 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 51-56 22074824-6 2011 ATP, statin or the selective P2X7 agonist BzATP also inhibited cell growth, and this inhibition was not seen in p110beta knock out cells. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 42-47 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 29-33 22349510-5 2012 Intriguingly, P2X4 knockdown resulted in significant suppression of cell death induced by ATP or P2X7 agonist BzATP. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 110-115 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 97-101 19379509-8 2009 RESULTS: (a) Co-application on the skin of the P2X7 specific agonist BzATP inhibited formation of DMBA/TPA-induced skin papillomas and carcinomas. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 69-74 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 47-51 19464323-6 2009 A-839977 potently (IC50=20-150 nM) blocked BzATP-evoked calcium influx at recombinant human, rat and mouse P2X7 receptors. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 43-48 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 107-111 20069573-4 2010 ATP and BzATP, a P2X7 agonist, induced cell death at concentrations that are described to activate the P2X7 receptor in mouse. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 8-13 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 17-21 20069573-4 2010 ATP and BzATP, a P2X7 agonist, induced cell death at concentrations that are described to activate the P2X7 receptor in mouse. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 8-13 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 103-116 19379509-19 2009 (c) The diminished pro-apoptotic effect of BzATP in mouse cancer keratinocytes is possibly the result of low expression of the P2X(7) receptor. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 43-48 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 127-142 19379509-20 2009 (d) Activation of P2X(7)-dependent apoptosis, e.g. with BzATP could be a novel chemotherapeutic growth-preventive modality for papillomas and epithelial cancers in vivo. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 56-61 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 18-24 19066285-5 2009 Benzoylbenzoyl-ATP (BzATP; a P2X7 agonist) induced transient translocation of PKCalpha to the basolateral membrane. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 0-18 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 29-33 19066285-5 2009 Benzoylbenzoyl-ATP (BzATP; a P2X7 agonist) induced transient translocation of PKCalpha to the basolateral membrane. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 20-25 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 29-33 18502993-1 2008 PURPOSE: Previously, the authors demonstrated that BzATP, a P2X(7) receptor agonist, enhanced corneal epithelial migration in vitro. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 51-56 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 60-75 18678987-5 2008 Thus, low concentrations (10 microM) of ATP (P2Y2 agonist) and UDP (P2Y6 agonist) evoked Ca2+ transient in a phospholipase C (PLC)-dependent manner, whereas the P2X7 agonist benzoylbenzoyl-ATP (BzATP, 500 microM) caused a sustained rise in [Ca2+]i. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 174-192 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 161-165 18678987-5 2008 Thus, low concentrations (10 microM) of ATP (P2Y2 agonist) and UDP (P2Y6 agonist) evoked Ca2+ transient in a phospholipase C (PLC)-dependent manner, whereas the P2X7 agonist benzoylbenzoyl-ATP (BzATP, 500 microM) caused a sustained rise in [Ca2+]i. 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate 194-199 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 161-165